We are very pleased to be granted Horizon 2020 funding. This significant amount of money, €2,100,000, will be spent on the validation of imILTCLS. The studies will be performed in collaboration with hospitals we have an established relationship with: in Marseille, France, Porto, Portugal and in Nottingham, the UK. The grant gives us stronger resources to bring imILTCLS to the market and to offer our method as an option in cancer treatment.
– CEO Lars-Erik Eriksson